Actinium Pharmaceuticals, Inc. announced that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) who are fit for intensive therapy has completed the planned dose escalation and patient enrollment. Patients in the fourth and final dose escalation cohort received 1.0 ?Ci/kg of Actimab-A with the standard CLAG-M dose regimen. This novel combination trial is being conducted at the Medical College of Wisconsin. Updated Phase 1 data is expected will be presented at the American Society of Hematology (ASH) Annual Meeting in December and Actinium expects to provide an update on the future clinical development of this combination by year end. Actimab-A CLAG-M combination data was presented at ASH 2020 from the first three dose cohorts, which highlighted: 100% remission rate (CR/CRi) in patients receiving 0.75 ?Ci/kg of Actimab-A with CLAG-M; 83% remission rate in patients who received 3 or fewer lines of prior treatment; 70% of patients achieving a remission were MRD negative; 67% of patients in the study achieved a remission including patients receiving 0.25 and 0.50 ?Ci/kg of Actimab-A, which has shown to be subtherapeutic as a single agent in prior studies; All patients had intermediate (N=5, 33%) or adverse (N=10, 67%) cytogenetics; Patients had a median of 2 prior therapies (range:1- 5) including prior Venetoclax/HMA (N=7,47%) or bone marrow transplant (N=8, 53%). These results compare favorably to outcomes with CLAG-M as a single agent, which was shown in a separate study to have a 55% overall response rate and a 39% MRD negativity rate.